1 in 2 diabetics suffer from Peripheral Neuropathy[1] during their lifetime

With Diabetes Mellitus being the leading cause[2] of Peripheral Neuropathy (PN), the increasing prevalence of PN is closely linked to the rise in the number of diabetic patients. PN including Diabetic Peripheral Neuropathy (DPN) is the result of damage to the nerves impacting quality of life of people as they are not able to go about their daily lives as comfortably. Symptoms of peripheral neuropathy include numbness, tingling, prickling, and burning sensations in the hands and feet. Besides diabetes mellitus, B vitamins deficiencies and aging are other high-risk factors leading to peripheral nerve damage.

FAST FACTS:

- In 2021, there were 393 million diabetic patients[3] in the Asia Pacific, Middle East, and African regions projected to rise to 603 million by 2045[3].

- With ~50 per cent [1] of diabetic patients indicating that they suffer from Peripheral Neuropathy, there will be an exponential growth in the number of patients in these regions with PN.

- Less than one-third of physicians recognize signs of DPN. Undiagnosed cases contributing greatly to the high rates of morbidity and mortality of diabetes[3]. Up to 50 per cent of patients are asymptomatic and therefore often remain undiagnosed and are at risk of insensate injury[4].

- If not diagnosed and treated early, DPN can develop into neuropathic pain which has a tremendous impact on the quality of life.

- To decrease the risk of DPN, regular screening, early detection and patient education are crucial for optimal treatment outcomes.

Aalok Agrawal, Senior Vice-President, P&G Health, Asia, India, Middle East & Africa said "As a partner to International Diabetes Federation (IDF), P&G Health is committed to continued efforts to raise awareness on Diabetes and its associated complications including Peripheral Neuropathy and Nerve Damage. Our 'Put Life Back in Your Hands' campaign is a large-scale collective awareness effort across 18 countries with consumers, healthcare professionals, pharmacists, medical and partner organisations to highlight the everyday challenges faced by people suffering from Peripheral Neuropathy, and the importance of timely diagnoses and treatment for an improved quality of life.

"With conditions such as diabetes and peripheral neuropathy underdiagnosed and untreated in our region, platforms such as World Diabetes Day also provide an opportunity for collective efforts on raising awareness and education for improved treatment outcomes. One such effort is P&G Health's 'Winning the Fight Against Neuropathy in Diabetic Patients' forum which will bring together globally renowned multidisciplinary medical experts with Healthcare Professionals and Pharmacists from across Asia-Pacific, Middle East, to share latest clinical guidance on diagnosing and treating diabetic nerve damage," he added.

For more information on the 'Winning the Fight Against Neuropathy in Diabetic Patients' forum, please write in to our media contacts, or click here to register the webinar as healthcare professional: WDDglobalwebinar

Disclaimer: Indications of Neurobion may differ in different countries, please check with your local healthcare professionals for more information.

P&G Health, the health care division of P&G company, drives consumer-centric innovation to empower our consumers to live healthier, and more vibrant lives. The P&G Health portfolio includes leading brands in Respiratory with Vicks and Nasivin, Pregnancy with Femibion and Clearblue, Oral Care with Crest and Oral-B, Vitamins and Minerals Supplementation with Bion3, Seven Seas, Evion and Sangobion, Digestive wellness with Metamucil, Prilosec OTC, Pepto Bismol and Align, Nerve Care with Neurobion and Pain Relief with Dolo-Neurobion.

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always, Ambi Pur, Ariel, Bounty, Charmin, Crest, Dawn, Downy, Fairy, Febreze, Gain, Gillette, Head & Shoulders, Lenor, Olay, Oral-B, Pampers, Pantene, SK-II, Tide, Vicks, and Whisper. The P&G community includes operations in approximately 70 countries worldwide.

References:

1. Kumar S, et al. Laser Therapy 2016;25: 141-144

2. Landmann G. Ars Medici. 2013;1: 18-21

3. International Diabetes Federation. IDF Diabetes Atlas. 10th edition; 2021.

4. Miranda-Massari JR, et al. Curr Clin Pharmacol. 2011;6: 260-273.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)